These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36059975)

  • 21. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
    Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
    Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.
    Lewis JH; Larrey D; Olsson R; Lee WM; Frison L; Keisu M
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):327-39. PubMed ID: 18793587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Update on Drug-induced Liver Injury.
    Devarbhavi H
    J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases.
    Teschke R; Zhu Y; Jing J
    J Clin Transl Hepatol; 2020 Jun; 8(2):200-214. PubMed ID: 32832401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM.
    Qin FL; Sang GY; Zou XQ; Cheng DH
    Can J Gastroenterol Hepatol; 2022; 2022():5914593. PubMed ID: 35369115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
    Rochon J; Protiva P; Seeff LB; Fontana RJ; Liangpunsakul S; Watkins PB; Davern T; McHutchison JG;
    Hepatology; 2008 Oct; 48(4):1175-83. PubMed ID: 18798340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potassium para-aminobenzoate and liver function test findings.
    Zarafonetis CJ; Dabich L; DeVol EB; Rossi C; Skovronski JJ
    J Am Acad Dermatol; 1986 Jul; 15(1):144-9. PubMed ID: 3487559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A revised electronic version of RUCAM for the diagnosis of DILI.
    Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
    Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals.
    Delgado A; Stewart S; Urroz M; Rodríguez A; Borobia AM; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM).
    Nin Chau T; Cheung WI; Ngan T; Lin J; Lee KW; Tat Poon W; Leung VK; Mak T; Tse ML;
    Clin Toxicol (Phila); 2011 Jan; 49(1):34-9. PubMed ID: 21114414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and pathological features in 138 cases of drug-induced liver injury].
    Lai RT; Wang H; Gui HL; Ye MZ; Dai WJ; Xiang XG; Zhao GD; Wang WJ; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):185-9. PubMed ID: 22475136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare Incidence of Acute Liver Injury with Potassium Para-Aminobenzoate Introduction.
    Al Attar L; Kilgore W
    Case Rep Gastroenterol; 2018; 12(2):230-233. PubMed ID: 29928188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-induced Liver Injury Caused by Phenprobamate: Strong Probability Due to Repeated Toxicity.
    Duzenli T; Tanoglu A; Akyol T; Kara M; Yazgan Y
    Euroasian J Hepatogastroenterol; 2019; 9(1):49-51. PubMed ID: 31988867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?
    Carson CC
    Tech Urol; 1997; 3(3):135-9. PubMed ID: 9422444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison.
    Lei X; Zhang J; Xu Q; Li J; Qian Y; Zhang J; Liu L; Zhong W; Wang Y; Han X; Tang J; Zeng M; Mao Y
    J Int Med Res; 2021 Aug; 49(8):3000605211039810. PubMed ID: 34433332
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment.
    Mullins C; Beaulac K; Sylvia L
    Ann Pharmacother; 2020 Jun; 54(6):526-532. PubMed ID: 31786964
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.
    Teschke R; Uetrecht J
    Ann Transl Med; 2021 Apr; 9(8):730. PubMed ID: 33987428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
    Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.